AAA August 2013 – Page 6

SetPoint pulses with $27m

UK-listed drugs company GlaxoSmithKline’s (GSK) new strategic corporate venturing fund for bioelectronic medicines and technologies has joined a consortium to investing in the $27m series D round for SetPoint Medical, a US-based biomedical technology company. Alongside GSK’s Action Potential Venture Capital fund in the round were corporate venturing peers from healthcare companies Covidien and Boston… Continue reading SetPoint pulses with $27m

Big Deal: GSK electrifies with first deal

The first deal by any fund is always scrutinised carefully, both within the company and without. So, UK-listed drugs company GlaxoSmithKline’s (GSK) new strategic corporate venturing fund for bioelectronic medicines and technologies’ decision to invest in the $27m round for SetPoint Medical offers plenty of opportunities for reading the tea leaves, as it were. Of… Continue reading Big Deal: GSK electrifies with first deal

Samsung lights up to Novaled

Asia electronics group Samsung is looking to gain greater control of the organic light-emitting diode, or OLED, technology as consumers favour thinner screens in smartphones and TV sets. It is hoping to get a piece of that market through a pending acquisition through its affiliate Cheil Industries, also known as Samsung Chemical, of German organic light-emitting diode (OLED) technology developer Novaled.